Eisai submits sBLA to FDA for Leqembi IV maintenance dosing in Alzheimer’s
Developed by Eisai and Biogen, Leqembi is humanised IgG1 monoclonal antibody indicated as an AD therapy for patients…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Apr 24
Developed by Eisai and Biogen, Leqembi is humanised IgG1 monoclonal antibody indicated as an AD therapy for patients…
28 Mar 24
The approval is supported by the safety and efficacy data from the INNO2VATE programme and post-marketing safety data…
28 Mar 24
Chubb today announced the launch of a new HealthTech industry practice in the UK.
26 Mar 24
The acquisition is expected to advance Nuvation Bio as a late-stage, international oncology firm in which its current…
26 Mar 24
Through the deal, the American pharma major gains access to NX-13, Landos Biopharma’s flagship asset, which is being…
26 Mar 24
Q32 Bio to focus on advancement of bempikibart (ADX-914) in ongoing atopic dermatitis (AD) and alopecia areata (AA)…
26 Mar 24
Unprecedented relapse risk reduction observed in CHAMPION-NMOSD trial underscores how Ultomiris may redefine patient journey for rare neurological…
26 Mar 24
XRP Healthcare is thrilled to announce a strategic partnership with Isansys Lifecare, a leading innovator in the digital…
26 Mar 24
TNO spin-off Peregrion brings science to the marketplace
25 Mar 24
The approval was based on the findings from the confirmatory Phase 3 MIRASOL trial in which Elahere treatment…